The U.S. Supreme Court on Monday temporarily preserved nationwide access to the abortion pill mifepristone through telemedicine and mail delivery, extending a pause on a lower court ruling that threatened to significantly limit how the medication is prescribed and distributed across the country.
Justice Samuel Alito issued the administrative order keeping the restrictions on hold until May 14, allowing patients to continue receiving the medication by mail while the nation’s highest court considers the next steps in the closely watched legal battle.
The dispute stems from a Republican-led lawsuit filed by the state of Louisiana challenging a federal policy adopted during former President Joe Biden’s administration that expanded access to abortion medication through remote healthcare services.
Legal Fight Centers on FDA Rule Changes
At the heart of the case is a 2023 rule issued by the U.S. Food and Drug Administration that removed the requirement for patients to obtain mifepristone during an in-person clinic visit. The policy change allowed healthcare providers to prescribe the medication through telemedicine consultations and ship it directly to patients by mail.
However, the New Orleans-based 5th U.S. Circuit Court of Appeals ruled earlier this month that the FDA’s policy should be blocked while litigation continues. That decision would have restored older restrictions requiring women to visit a clinician physically before receiving the medication.
Drug manufacturers Danco Laboratories and GenBioPro, which produce generic and branded versions of mifepristone, quickly appealed the ruling to the Supreme Court, arguing that reinstating the restrictions would create widespread confusion and reduce access to reproductive healthcare nationwide.
The Supreme Court first intervened on May 4, temporarily pausing the appeals court decision to give the justices more time to review the matter. Monday’s extension means the lower court ruling remains suspended for now.
Mifepristone at the Center of U.S. Abortion Debate
Medication abortion has become the most common method of ending pregnancies in the United States. The standard process involves two medications — mifepristone followed by misoprostol — and accounts for nearly two-thirds of abortions nationwide.
Medical experts and reproductive rights advocates say limiting mail distribution and telemedicine access could disproportionately affect women living in rural areas or states with strict abortion laws, where clinics may be scarce or inaccessible.
The case has once again placed abortion rights at the center of America’s political and legal debate ahead of November’s congressional midterm elections, with Republicans seeking to maintain control of Congress while Democrats continue campaigning on reproductive healthcare protections.
Ongoing Fallout From Roe v. Wade Reversal

The legal battle over mifepristone follows the Supreme Court’s landmark 2022 decision overturning Roe v. Wade, which had guaranteed a constitutional right to abortion for nearly five decades.
Since that ruling, 13 U.S. states have enacted near-total abortion bans, while several others have imposed severe restrictions on reproductive healthcare services.
Louisiana, which filed the latest lawsuit against the FDA in 2025, argued that easing access to abortion pills violated federal law and undermined the state’s strict abortion policies. State officials claimed the telemedicine rule contributed to a sharp increase in medication abortions despite Louisiana’s near-total ban on the procedure.
Supreme Court Faces Renewed Pressure
The Supreme Court previously rejected an earlier attempt by anti-abortion groups and doctors to roll back FDA policies expanding access to mifepristone. In a unanimous ruling in 2024, the justices found the challengers lacked standing to sue.
This latest case, however, presents a different legal pathway and could have far-reaching implications for federal authority over drug regulation and access to reproductive healthcare.
For now, the court’s temporary order keeps the current system in place, allowing patients to continue receiving abortion medication through telemedicine appointments and mail delivery while the justices deliberate.
The decision expected later this month could shape abortion access across the United States for years to come and further intensify one of the country’s most divisive political battles.















